B16-F10 Syngeneic Model Service for Melanoma

The B16-F10 syngeneic model of melanoma grows a pigmented, aggressively metastatic murine melanoma in fully immunocompetent C57BL/6 hosts, serving as the field’s canonical platform for metastasis, checkpoint-combination and nanomedicine research. Alfa Cytology delivers the complete B16-F10 workflow—authenticated cell banking, subcutaneous, intradermal, intravenous or intracardiac implantation, balanced randomization, scheduled dosing and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of B16-F10 Syngeneic Model for Melanoma

B16-F10’s ancestry begins in 1954, when a spontaneous melanoma was discovered behind the ear of a C57BL/6 mouse—one of the oldest continuously used tumor lines in existence. The F10 identity was forged two decades later by Isaiah Fidler, whose experimental-metastasis method transformed the field: parental B16 cells were injected intravenously, the lung colonies they seeded were harvested, expanded and re-injected, and the cycle was repeated ten times—each round enriching for cells that survive, arrest and colonize. The product, B16-F10 (ATCC CRL-6475), doubles in culture in about 17 hours (its low-metastasis sibling B16-F1, selected for a single round, needs 22), grows as an adherent mix of spindle-shaped and epithelial-like cells, and—critically for readouts—stays pigmented. The line carries the classic melanoma genetics: Braf and Met amplifications with Pten and Trp53 missense mutations, and its biology is dominated by a ferocious lung tropism that later extends to liver, brain, lymph nodes, ovaries and adrenals.

Fig 1. B16-F10 cell implantation into the ear pinnae of C57BL/6J mice; tumor take rate increases with post-implantation time, standardizing inoculation for the B16-F10 syngeneic model. (Potez, Marine, et al., 2018)

Few models offer B16-F10’s anatomical versatility: subcutaneous flank implants (2 × 10⁵ to 1 × 10⁶ cells) support routine efficacy work with spontaneous lymph-node and lung spread; intradermal implantation restores the cutaneous niche; tail-vein inoculation of 2 × 10⁵ cells produces countable pulmonary colonies; intracardiac injection seeds brain and bone; pinna engraftment has been optimized for regional-node metastasis; and intrathecal delivery models leptomeningeal disease—though its aggression there leaves very short treatment windows. Immunologically the tumor is a hard case: poorly immunogenic and documented as resistant to single-agent anti-PD-1, anti-PD-L1 and anti-CTLA-4, which makes it the proving ground for combination strategies, vaccine adjuvants, oncolytic platforms and nanomedicine—recent exemplars including manganese-based PD-1-engineered nanoplatforms, platelet-targeting plus checkpoint blockade, ferrocene hydrogels and engineered bacterial photodynamic therapy. Two practical signatures deserve mention: melanin lets investigators eyeball tumor burden directly, yet absorbs light and must be accounted for in optical and photothermal designs; and the luciferase version (ATCC CRL-6475-LUC2) restores quantitative whole-body imaging. Caveats are honest ones: weak baseline immunogenicity, mutation diversity short of human melanoma, and brutally compressed windows in the most aggressive formats.

Cell Line Information: B16-F10

Key characteristics of B16-F10 and its documented derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, bioluminescence imaging and flow-cytometry capabilities in-house, Alfa Cytology molds every B16-F10 engagement around the sponsor’s question—selecting flank, intradermal, intravenous, intracardiac or intrathecal formats, calibrating inoculum and schedule, and pairing dosing with metastasis counts and immune readouts for clean, decision-grade preclinical data.

Workflow of B16-F10 Syngeneic Model Construction

Construction of the B16-F10 syngeneic model is an implantation workflow whose quality rests on verified cells, vigorous C57BL/6J recipients, route-matched technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: B16-F10 or B16-F10-LUC2 stocks are cleared by mycoplasma PCR and STR-authenticated (subline multiplicity demands it); melanin/dopa positivity is documented as an identity feature, and luciferase expression is titrated in vitro with D-luciferin where imaging readouts are required.
2. Prepare recipients: C57BL/6J mice (typically 6–8 weeks old) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS at the route-specific working concentration (flank 2 × 10⁵–1 × 10⁶ cells in 100 µL; tail vein 2 × 10⁵–5 × 10⁵ cells in 100–150 µL; intracardiac or intrathecal formats use smaller volumes under anesthesia).
4. Implant: cells are delivered subcutaneously into the flank or intradermally for primary-tumor formats, or intravenously via tail vein, intracardially or intrathecally for dissemination formats, with consistent technique for each route.
5. Randomize: flank-format animals are grouped when tumors reach palpability (typically 50–100 mm³), balanced by tumor volume and body weight; dissemination-format cohorts are randomized at inoculation.
6. Dose and follow: test articles are administered on schedule; flank tumors are measured with calipers two to three times weekly (volume typically 0.52 × length × width²), with bioluminescence substituted for labeled cohorts; body weight and clinical status are logged daily in aggressive formats.
7. Terminate and analyze: primary tumors are resected and weighed; lungs are counted for surface colonies and confirmed by H&E; lymph nodes, brain and bone are examined for the relevant dissemination formats; tissues enter histopathology, immunohistochemistry, flow cytometry and molecular analysis.

Fig 2. B16-F10 Syngeneic Model construction workflow.

Case Study-B16-F10 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the B16-F10 platform: establishment-phase optimization of inoculum and route, in vivo growth tracking by caliper or bioluminescence, combination-immunotherapy and nanomedicine intervention studies, and systematic pulmonary and multi-organ metastasis quantification with matched histological and immune readouts. Representative growth curves, metastasis datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

The most-used melanoma model in history still punishes imprecision—and rewards the operational breadth Alfa Cytology maintains:

• Route-breadth spanning flank, intradermal, tail-vein, intracardiac, pinna and intrathecal formats.
• STR-disciplined banking acknowledging the B16 family’s subline multiplicity, with melanin documented as an identity feature.
• Pigmentation-aware imaging design that turns melanin from an artifact into a feature.
• Checkpoint-combination expertise in a documented single-agent-resistant tumor.
• Nanomedicine and drug-delivery evaluation reflecting the model’s documented precedents.
• Compressed-window management for the most aggressive formats, with humane endpoints defined up front.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the B16-F10 syngeneic melanoma model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.